EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 257 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Determining Fluid Requirements March 26, 2021 FDA Approves HPV Tests That Allow for Self-Collection in a Health... July 24, 2024 England moves to a single-dose HPV vaccine June 21, 2023 Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread January 5, 2024 Load more HOT NEWS Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer...
